title: ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).
abstract: STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).
authors.affiliation: Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
mesh_terms: D000818:Animals; D001418:Baclofen / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy* / Q000453:epidemiology; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D058786:GABA-B Receptor Agonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009488:Neurosciences; D012958:Societies, Scientific
chemical_list: D058786:GABA-B Receptor Agonists; D001418:Baclofen